Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
We are proud to share that Orcosa has been selected by BioNJ to present at the 2025 BioPartnering Conference on May 13th in Jersey City, NJ. Co-founder and COO, Vincent T. Mileto will deliver “Modernizing The Way Medicines Are Taken,” highlighting our RITe™ orally disintegrating tablet platform and its potential to transform drug delivery. “It’s an honor to be recognized among New Jersey’s innovators,” Mileto said. “We look forward to demonstrating how RITe™ can be used to create safer, faster-acting, and easier-to-take medicines.”
BioNJ’s 15th Annual BioPartnering Conference, developed in partnership with J.P. Morgan Chase, will bring together nearly 400 public and private company investors, life sciences professionals, and academic partners from the Northeast to Mid-Atlantic region to engage in one-on-one partnering sessions, company presentations, and exhibits designed to foster meaningful collaborations and drive innovations forward. Pharmaceutical sponsors for the conference include Johnson & Johnson, Merck, and Pfizer, among others.